Webinar Summary
Patients with neuromuscular disease need safer, more effective treatment options. Inefficient delivery forces high systemic vector doses, increasing off-target liver exposure, trading safety for the chance at efficacy. More efficient delivery makes gene therapies more effective, safer, and cheaper to produce, empowering patients with genetic agency, the ability to take action at the genetic level to live a healthier life.
Dyno Therapeutics applies AI to solve gene delivery through machine learning models trained on large-scale in vivo measurements to design AAV capsids for muscle delivery, including Dyno-bn8, which achieves therapeutic delivery at a 25-fold lower dose than existing muscle gene therapies.
On Wednesday, September 23 at 8 AM PT, Dyno Therapeutics and Curi Bio present jointly generated data from a study putting Dyno-bn8 and other in vivo validated myotropic capsids through Curi Bio’s human iPSC-derived 3D Engineered Muscle Tissue (EMT) platform. Every Dyno engineered capsid tested expressed in the human skeletal muscle model. The teams ran the study on both Curi Bio systems, the 24-well Mantarray™ and the new 96-well Nautilai Plus™, measuring transgene expression and tissue contractility in one workflow. The 96-well format reproduced the 24-well dose responses at higher throughput.
The study also revealed how Curi Bio’s platform can be used for screening payloads. Dyno’s AI can now be applied to engineering payloads, expanding the range of diseases that gene therapy can address by designing candidates that go beyond what could previously be discovered. Starting with capsids of known in vivo performance, the same platform can efficiently screen payloads to determine which capsid/payload combination to advance into in vivo experiments.
Join Dr. Megan Cramer and Dr. Thomas Leahy for a data-rich session on how AI-designed capsids and scalable human muscle tissue combine into a faster, cheaper front end for muscle and neuromuscular gene therapy, and how to access Dyno's technology through the Dyno Frontiers Network.
Date & Time
Wednesday, September 23, 2026
8:00-9:00 am PDT (11:00 am EDT / 5:00 pm CEST)
Speaker Details
Dr. Megan Cramer
Senior Principal Scientist at Dyno Therapeutics
Dr. Megan Cramer
Senior Principal Scientist at Dyno Therapeutics
Dr. Cramer is a muscle biologist with experience developing gene therapies for neuromuscular diseases. As a Senior Principal Scientist at Dyno Therapeutics, she draws on this expertise to advance the characterization of AI-engineered AAV capsids. She leads in vivo study design to identify and validate the most promising next-generation capsids and has developed the histology and quantitative imaging pipeline used to evaluate their performance. She is driven by the goal of delivering safer, more effective AAV-based therapies to patients with neuromuscular diseases.
Dr. Thomas Leahy
Field Applications Scientist at Curi Bio
Dr. Thomas Leahy
Field Applications Scientist at Curi Bio
Dr. Leahy is a Field Applications Scientist at Curi Bio with a background in musculoskeletal and cardiovascular research, biomechanics, and 3D tissue engineering. He supports the adoption of Curi Bio’s technologies by collaborating with internal scientists and partnering directly with customers to expand applications across cardiac, skeletal muscle, and neuromuscular research.
Register Now to Secure Your Spot
Submit the form below to register for this live webinar + Q&A session. Registration will close 24 hours before the event.
Please contact us with any questions or concerns.